CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 33 enrolled
Drug / intervention
Carnosine +1 moredrug
Likely dose
Carnosine 500mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00810368
NCT00810368Phase 2Completed
CompareCT.gov

Carnosine Versus Placebo Treatment Study in Gulf War Illness (GWI)

Georgetown University·interventional·Posted Dec 18, 2008·Updated Jun 28, 2019

In Brief

A Phase 2 clinical trial evaluating Carnosine and Placebo for Persian Gulf Syndrome. Completed, enrolled 33 participants across 1 site.

Detailed Summary

The purpose of this study is to perform a randomized double-blind, placebo-controlled, 12 week study of the effects of carnosine on cognitive, psychometric, autonomic, and muscle strength outcomes in 100 GWI subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPersian Gulf Syndrome
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 18, 2008
Enrollment StartAug 1, 2008
Primary CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 17.5 years ago

Interventions

Carnosinedrug

500mg Carnosine x2 daily

Placebodrug

Microcrystalline cellulose placebo tablets x2 daily